Nutrition Industry Executive (NIE) magazine asked Vishal Shah, director of Nutriventia Limited (Mumbai. India), about advances in extraction, manufacturing and delivery technologies. Here’s what he had to say…

NIE: For natural relief of pain and inflammation, what are the most exciting recent advances in extraction, manufacturing and delivery technologies?

Shah: The industry has been focused on the extraction of bioactives to be used for these applications. However, our attention is on how we can use our proprietary technologies to enhance the benefits of these bioactives, either by improving usability, palatability, or by reducing the dosage—all attributes that add more convenience for the consumer. I strongly believe that delivery technologies will be the key differentiators in the coming years. We saw this gap and have put all our resources into making this accessible to the supplement industry.

Let’s consider TurmXTRA60N, our branded turmeric ingredient with excellent anti-inflammatory properties. For centuries, turmeric root has been widely used to treat inflammation. Before selective extraction, a large amount of root powder needed to be consumed to see beneficial results. With advancements in extraction technologies, the industry used to standardize curcuminoids through selective extraction and target specific inflammation pathways for better clinical outcomes. Approximately 1.5 g of 95 percent curcuminoids is now accepted as the gold standard. However, to be frank, this is still high since it translates to two to four doses daily and results in missed doses by consumers leading to sub-par clinical outcomes.

Here is where advancement in delivery technologies comes to the rescue. The ability to load a higher amount of curcuminoids (minimum 60 percent) with a diet-sourced natural excipient enabled us to reduce the effective dose to just 50 mg. We further proved that this dose produced equivalent plasma levels compared with 1.5 g of 95 percent curcuminoids and clinically validated it with multiple clinical trials.

Feature